Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADIANT: Adjuvant Erlotinib in Stage IB-IIIA NSCLC
NCT00373425Phase 3Completed
- Sponsor
- OSI Pharmaceuticals
- Start
- Sep 2006
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Erlotinib with Placebo (2 arms). Primary endpoint: Disease Free Survival at 78 months. Started Sep 2006; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00373425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00373425.